← Eichor
Condition: Alzheimer Disease With Psychosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Alzheimer Disease With Psychosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
Phase 2 · 3 location(s) · MapLight Therapeutics · NCT07459660A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT
Phase 3 · 129 location(s) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT05511363A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Dise
Phase 3 · 22 location(s) · Bristol-Myers Squibb · NCT06947941Tau Networks in Psychotic Alzheimer's Disease
Phase N/A · 1 location(s) · Northwell Health · NCT05847192A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
Phase 1 · 1 location(s) · Luye Pharma Group Ltd. · NCT07230652A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Phase 3 · 292 location(s) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT06585787Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia
NA · 11 location(s) · Advanced Technology & Communications · NCT06088121A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Phase 2 · 40 location(s) · MapLight Therapeutics · NCT06887192Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associate
Phase 3 · 429 location(s) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT05980949Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders
NA · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT07509125A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Phase 2 · 65 location(s) · Intra-Cellular Therapies, Inc. · NCT06540833A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT
Phase 3 · 154 location(s) · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT06126224ACP-204 in Adults With Alzheimer's Disease Psychosis
Phase 2/Phase 3 · 148 location(s) · ACADIA Pharmaceuticals Inc. · NCT06159673
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.